Dermata Therapeutics, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Dermata Therapeutics, Inc. (DRMA) on September 21, 2022. The Company is an emerging growth company incorporated in Delaware with principal executive offices in San Diego, California. The report addresses a corporate governance amendment adopted by the Board of Directors.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a change to the Company's Bylaws and does not contain financial performance data.
Material Changes
On September 21, 2022, the Board of Directors adopted an amendment to the Company's Amended and Restated Bylaws. The amendment modifies Section 1.6 of Article I to decrease the quorum requirement for stockholder meetings. The requirement was reduced from a majority of the voting power of shares entitled to vote to one-third of the voting power of shares entitled to vote, present in person or represented by proxy.
Guidance, Outlook, and Risks
The filing contains no management commentary regarding financial guidance, future outlook, risks, contingencies, or unusual items. The document serves solely to disclose the amendment to the Bylaws.
Key Facts for Investor Verification
- The quorum requirement for stockholder meetings has been lowered from a majority to one-third of voting power.
- The amendment was adopted by the Board of Directors on September 21, 2022.
- The full text of the Amendment is filed as Exhibit 3.1 with this report.
- The Company is classified as an emerging growth company.